Volpara Health Technologies (ASX: VHT) has been granted another patent in the United States for its integrated breast care platform which assists in the delivery of personalised breast care.
CEO, Dr Ralph Highnam, said this latest grant protects the unique features of the company’s VolparaEnterprise and VolparaLive! software.
Titled “System and Apparatus for Clinical Decision Optimisation” (US granted patent number US10/984528), this US grant is the latest in the international extension of the patent.
“The patent granted by the US Patent and Trademark Office protects key features of our current products, and the advantages that those products offer clinicians and patients,” Dr Highnam said.
“The patent also protects developments that Volpara will integrate into new products. It helps secure our freedom to operate and build upon our foundation patents, which are now approaching 12 years since grant.”
Volpara currently holds 96 patents across 25 countries, granted since 2009.
The Company uses a combination of intellectual property rights—patents, trade secrets, copyright, and trademarks—to ensure effective, enforceable protection of its products and to facilitate its sales and growth strategy.
VolparaEnterprise helps clinicians monitor workflow efficiency and work quality by measuring how long it takes to acquire images, how quickly patients are screened, and how effectively technologists position patients.
VolparaLive! automatically analyses patient positioning and compression and provides real- time feedback to technologists.
VolparaEnterprise and VolparaLive! work together to provide state-of-the-art workflow solutions that reduce breast care clinics’ costs and enhance their revenue opportunities and improve diagnosis and treatment options for women who may be susceptible to breast
